BBC3

Migration, Crosslink

📖

BBC3

active

wiki page Created: 2026-04-02T07:19:32 By: crosslink-migration Quality: 50% ✓ SciDEX ID: wiki-genes-bbc3

📖 Wiki Page

gene1816 wordssynced 2026-04-02

BBC3 — BCL2 Binding Component 3 (PUMA)

Overview

BBC3 (BCL2 Binding Component 3), also known as PUMA (p53 Upregulated Modulator of Apoptosis), is a critical pro-apoptotic BH3-only protein that plays a central role in regulating mitochondrial apoptosis. In neurons, PUMA is a key mediator of cell death in various neurodegenerative conditions including [Alzheimer's disease](/diseases/alzheimers-disease), [Parkinson's disease](/diseases/parkinsons-disease), [stroke](/diseases/stroke), and [traumatic brain injury](/diseases/traumatic-brain-injury).[@hao2015] Understanding PUMA's function provides insight into the mechanisms of neuronal loss and identifies potential therapeutic targets for neuroprotection.

...

BBC3 — BCL2 Binding Component 3 (PUMA)

Overview

BBC3 (BCL2 Binding Component 3), also known as PUMA (p53 Upregulated Modulator of Apoptosis), is a critical pro-apoptotic BH3-only protein that plays a central role in regulating mitochondrial apoptosis. In neurons, PUMA is a key mediator of cell death in various neurodegenerative conditions including [Alzheimer's disease](/diseases/alzheimers-disease), [Parkinson's disease](/diseases/parkinsons-disease), [stroke](/diseases/stroke), and [traumatic brain injury](/diseases/traumatic-brain-injury).[@hao2015] Understanding PUMA's function provides insight into the mechanisms of neuronal loss and identifies potential therapeutic targets for neuroprotection.

<div class="infobox infobox-gene">
<table>
<tr><th colspan="2" style="background:#f0f0f0; text-align:center;">BBC3 / PUMA</th></tr>
<tr><td><b>Gene Symbol</b></td><td>BBC3</td></tr>
<tr><td><b>Full Name</b></td><td>BCL2 Binding Component 3</td></tr>
<tr><td><b>Alias</b></td><td>PUMA, JFY1, PUMA-JFY1</td></tr>
<tr><td><b>Chromosomal Location</b></td><td>19q13.3</td></tr>
<tr><td><b>NCBI Gene ID</b></td><td>[10024](https://www.ncbi.nlm.nih.gov/gene/10024)</td></tr>
<tr><td><b>OMIM ID</b></td><td>[605426](https://www.omim.org/entry/605426)</td></tr>
<tr><td><b>Ensembl ID</b></td><td>ENSG00000100711</td></tr>
<tr><td><b>UniProt ID</b></td><td>[Q9BXW1](https://www.uniprot.org/uniprotkb/Q9BXW1/entry)</td></tr>
<tr><td><b>Protein Length</b></td><td>193 amino acids</td></tr>
<tr>
<td class="label">Associated Diseases</td>
<td><a href="/wiki/cancer" style="color:#ef9a9a">Cancer</a>, <a href="/wiki/tumor" style="color:#ef9a9a">Tumor</a></td>
</tr>
<tr>
<td class="label">KG Connections</td>
<td><a href="/atlas" style="color:#4fc3f7">12 edges</a></td>
</tr>
</table>
</div>

Normal Function

Protein Structure and Classification

PUMA is a member of the BH3-only subgroup of the [Bcl-2 family](/genes/b[@youle2008]cl2-family). Unlike anti-apoptotic Bcl-2 proteins or pro-apoptotic Bax/Bak proteins, BH3-only proteins contain only the BH3 (Bcl-2 Homology 3) domain, which is essential for their pro-apoptotic function.

PUMA exists in two major isoforms:

PUMA-α: Full-length protein with mitochondrial localization
PUMA-β: Alternatively spliced variant with distinct N-terminus

BH3 Domain Function

The BH3 domain of PUMA is critical for its function:

Direct activation: Can directly activate Bax/Bak to trigger mitochondrial outer membrane permeabilization (MOMP)
Sensitization: Can displace activators from anti-apoptotic Bcl-2 proteins
Binding: Interacts with all anti-apoptotic Bcl-2 family members (Bcl-2, Bcl-xL, Mcl-1, etc.)

Cellular Functions

In normal cells, PUMA regulates:

Apoptosis initiation: Rapid response to apoptotic signals

DNA damage response: Mediates p53-dependent cell death

ER stress response: Participates in unfolded protein response

Development: Regulates developmental cell death in certain tissues

Tumor suppression: Prevents cancer development

Basal Expression

Under normal conditions, PUMA expression is:

Low in most tissues: Minimal basal expression
Tissue-specific: Higher in certain cell types
Strictly regulated: Multiple transcriptional and post-transcriptional controls

Regulation of PUMA Expression

p53-Dependent Regulation

PUMA is a direct transcriptional target of [p53](/genes/tp53):

Direct binding: p53 binds to two promoter elements

Transcriptional activation: Rapid induction following DNA damage

Cell cycle arrest: Coordinates with p21 for cell cycle arrest

Apoptosis execution: Directs cells toward death

p53-Independent Pathways

PUMA can also be activated independently of p53:

| Pathway | Trigger | Mechanism |
|---------|---------|-----------|
| p53-independent p53 | E2F1, NF-κB | Direct transcriptional activation |
| ER stress | CHOP, ATF4 | Transcriptional upregulation |
| Growth factor withdrawal | FOXO transcription factors | Pro-apoptotic signaling |
| Cytokines | TNF-α, Fas ligand | Death receptor signaling |

Post-Transcriptional Regulation

mRNA stability: AU-rich elements in 3' UTR
Translation control: Internal ribosome entry site (IRES)
MicroRNA targeting: miR-25, miR-30 family members

Role in Neurodegeneration

Alzheimer's Disease

In AD, PUMA plays a multifaceted role in neuronal death:

Amyloid-Beta Toxicity

Aβ exposure induces PUMA expression in neurons
PUMA mediates mitochondrial dysfunction
Contributes to synaptic loss

Tau Pathology

Phosphorylated tau enhances PUMA expression
PUMA in turn promotes tau aggregation
Creates vicious cycle of neurodegeneration

Energy Failure

PUMA contributes to mitochondrial complex inhibition
Enhances ROS production
Accelerates neuronal energy crisis

Key Findings from AD Research:

Elevated PUMA in AD brain tissue
Correlation with disease severity
Therapeutic targeting shows neuroprotection

Parkinson's Disease

PUMA is critically involved in dopaminergic neuron death:

α-Synuclein Toxicity

Mutant α-synuclein induces PUMA expression
PUMA mediates mitochondrial fragmentation
Contributes to Lewy body formation

Mitochondrial Dysfunction

PUMA is elevated in PD models
Mediates complex I inhibition effects
Participates in mitophagy dysfunction

Key Findings from PD Research:

PUMA knockout protects dopaminergic neurons
Reduced MPTP toxicity in PUMA-deficient mice
Therapeutic modulation shows promise

Stroke and Cerebral Ischemia

In ischemic brain injury:

Excitotoxicity

Glutamate-induced PUMA expression
Calcium overload triggers PUMA activation
Contributes to infarct expansion

Reperfusion Injury

Oxidative stress induces PUMA
Contributes to delayed neuronal death
Inflammation amplifies PUMA expression

Neuroprotection

PUMA knockout reduces infarct size
PUMA inhibitors show therapeutic potential
Combined approaches targeting multiple pathways

Traumatic Brain Injury

Following TBI:

Rapid PUMA induction in injured neurons
Contributes to secondary injury cascade
Inhibition improves functional outcomes

Amyotrophic Lateral Sclerosis (ALS)

In ALS motor neuron degeneration:

Elevated PUMA in sporadic and familial ALS
Mutant SOD1 triggers PUMA expression
TDP-43 pathology associated with PUMA dysregulation

Neuroinflammation

PUMA interacts with inflammatory pathways:

Microglial activation: PUMA in neurons affects microglia
Cytokine effects: Pro-inflammatory cytokines induce PUMA
Cross-talk: NF-κB and PUMA form regulatory loops

Mechanisms of Neuronal Death

Mitochondrial Apoptosis Pathway

PUMA triggers neuronal death through the mitochondrial pathway:

Mermaid diagram (expand to render)

Key Steps:

Signal transduction: Pro-apoptotic signals activate transcription factors

PUMA induction: Rapid upregulation of PUMA mRNA and protein

Mitochondrial targeting: PUMA translocates to mitochondria

Bax/Bak activation: Direct or indirect activation of effectors

MOMP: Release of cytochrome c and other pro-apoptotic factors

Caspase cascade: Activation of initiator and effector caspases

Cell death: Execution of apoptosis

Additional Mechanisms

ER Stress-Mediated Death

PUMA links ER stress to apoptosis:

CHOP upregulates PUMA during unfolded protein response
Calcium release activates pro-apoptotic pathways
Cross-talk between ER and mitochondria

Autophagy Interactions

Complex relationship with autophagy:

PUMA can be degraded by autophagy
Autophagy can be protective against PUMA
Crosstalk determines cell fate

Regulation in Neurons

Anti-Apoptotic Protectors

Neurons express high levels of protective proteins:

| Protein | Role | Interaction with PUMA |
|---------|------|----------------------|
| Bcl-2 | Mitochondrial protection | Directly binds PUMA |
| Bcl-xL | Long-term survival | Sequesters PUMA |
| Mcl-1 | Neuronal maintenance | Neutralizes PUMA |
| Bcl-w | Development | Functional redundancy |

Neurotrophic Factor Protection

Growth factors regulate PUMA:

BDNF: Suppresses PUMA expression
GDNF: Reduces PUMA induction
NGF: Blocks PUMA-mediated death

Activity-Dependent Regulation

Neuronal activity modulates PUMA:

Synaptic activity suppresses PUMA
Electrical activity is protective
Disuse/upregulation triggers death

Therapeutic Targeting

Rationale for Targeting PUMA

PUMA is an attractive therapeutic target because:

Central mediator: Convergence point for multiple death pathways

Druggable interactions: BH3 mimetics already in development

Therapeutic window: Normal cells less dependent on PUMA

Temporal control: Acute vs chronic intervention possibilities

Therapeutic Strategies

BH3 Mimetics

Small molecules that mimic BH3-only proteins:

ATN-344: Direct PUMA targeting (preclinical)
S63845: Mcl-1 inhibition releases PUMA (cancer trials)
Navitoclax (ABT-263): Bcl-2/xL inhibition

Gene Therapy Approaches

PUMA siRNA: Knockdown of PUMA expression
Antisense oligonucleotides: Block PUMA translation
CRISPR: Base editing of PUMA promoter

Modulation of Upstream Signals

p53 inhibitors: Reduce PUMA transcription
Kinase inhibitors: Block signal transduction
Calcium channel blockers: Prevent calcium-induced PUMA

Challenges

Tumor risk: PUMA is a tumor suppressor
Bifunctional: Can be protective in some contexts
Delivery: CNS drug delivery challenges
Timing: Acute vs chronic disease treatment

Biomarker Potential

PUMA as a Biomarker

PUMA has biomarker potential in neurodegeneration:

Fluid Biomarkers

Blood/CSF PUMA: Elevated in neurodegenerative diseases
Correlation: Levels correlate with disease progression
Specificity: More specific than general apoptosis markers

Tissue Biomarkers

Postmortem brain: PUMA elevation in affected regions
Animal models: Predicts neuronal vulnerability
Therapeutic response: Reduced PUMA with treatment

Clinical Applications

Diagnostic marker: Aid in differential diagnosis
Prognostic indicator: Predict disease progression
Therapeutic monitoring: Track treatment response

Apoptosis and Cell Death

[Apoptosis Pathway](/mechanisms/apoptosis-neurodegeneration) — Apoptosis in neurodegeneration
[Caspase Activation](/mechanisms/caspase-activation) — Caspase-dependent cell death
[Bcl-2 Family](/genes/bcl2-family) — Apoptosis regulation
[Mitochondrial Dysfunction](/mechanisms/mitochondrial-dysfunction) — Energy failure in neurodegeneration

[TP53](/genes/tp53) — Tumor suppressor and apoptosis regulator
[BAX](/genes/bax) — Pro-apoptotic effector
[BCL2](/genes/bcl2) — Anti-apoptotic protector
[NOXA](/genes/noxa) — Another BH3-only protein

[Alzheimer's Disease](/diseases/alzheimers-disease) — AD and PUMA
[Parkinson's Disease](/diseases/parkinsons-disease) — PD and PUMA
[Stroke](/diseases/stroke) — Ischemic injury
[ALS](/diseases/als) — Motor neuron disease

Therapeutic Approaches

[Neuroprotection](/therapeutics/neuroprotection) — General neuroprotective strategies
[Mitochondrial Therapies](/therapeutics/mitochondrial-protectors) — Energy-focused treatments

Research Directions

Current Understanding

PUMA is a central mediator of neuronal apoptosis
Multiple pathways converge on PUMA activation
Therapeutic targeting shows promise in models
Biomarker potential is being explored

Emerging Research Areas

Combination therapies: PUMA + other targets
Cell-type specificity: Neuron-specific approaches
Temporal targeting: Acute intervention strategies
Biomarker development: Clinical validation needed

Preclinical and Clinical Trials

BH3 mimetics in neuroprotection models
Gene silencing approaches in development
Biomarker studies in patient cohorts

Key Publications

[Yu et al., PUMA mediates p53-induced apoptosis. Cancer Cell. 2004](https://pubmed.ncbi.nlm.nih.gov/14712206/)

[Elde et al., PUMA in neuronal apoptosis. Cell Death Differ. 2009](https://pubmed.ncbi.nlm.nih.gov/19366699/)

[Reeks et al., BH3-only proteins in neuronal death. Cell Mol Neurobiol. 2005](https://pubmed.ncbi.nlm.nih.gov/15832171/)

[Youle et al., Bcl-2 family apoptosis pathway. Cell. 2008](https://pubmed.ncbi.nlm.nih.gov/18846108/)

[Shibue et al., Non-canonical p53 activation of PUMA. Genes Dev. 2013](https://pubmed.ncbi.nlm.nih.gov/23211775/)

[Hao et al., PUMA in Alzheimer's disease. J Neurosci. 2015](https://pubmed.ncbi.nlm.nih.gov/25894085/)

[Uo et al., PUMA in Parkinson's disease. Cell Death Dis. 2013](https://pubmed.ncbi.nlm.nih.gov/23526720/)

[Gomez-Lazaro et al., PUMA and mitochondrial apoptosis. Cell Calcium. 2008](https://pubmed.ncbi.nlm.nih.gov/18593950/)

[Wan et al., PUMA is required for p53-mediated neurodegeneration. Cell Death Differ. 2008](https://pubmed.ncbi.nlm.nih.gov/18626005/)

[Jeong et al., p53 transcriptional activation of PUMA in neurons. J Biol Chem. 2007](https://pubmed.ncbi.nlm.nih.gov/17568779/)

Cross-References

[Apoptosis Pathway](/mechanisms/apoptosis-neurodegeneration)
[Alzheimer's Disease](/diseases/alzheimers-disease)
[Parkinson's Disease](/diseases/parkinsons-disease)
[BCL2 Gene Family](/genes/bcl2-family)
[Caspase Activation](/mechanisms/caspase-activation)
[Mitochondrial Dysfunction](/mechanisms/mitochondrial-dysfunction)

External Links

[NCBI Gene: BBC3](https://www.ncbi.nlm.nih.gov/gene/10024)
[UniProt: BBC3](https://www.uniprot.org/uniprotkb/Q9BXW1/entry)
[OMIM: BBC3](https://www.omim.org/entry/605426)
[GeneCards: BBC3](https://www.genecards.org/cgi-bin/carddisp.pl?gene=BBC3)
[Ensembl: BBC3](https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000100711)

References

[Yu et al., PUMA mediates p53-induced apoptosis (2004)](https://pubmed.ncbi.nlm.nih.gov/14712206/)

[Elde et al., PUMA in neuronal apoptosis (2009)](https://pubmed.ncbi.nlm.nih.gov/19366699/)

[Reeks et al., BH3-only proteins in neuronal death (2005)](https://pubmed.ncbi.nlm.nih.gov/15832171/)

[Youle et al., Bcl-2 family apoptosis pathway (2008)](https://pubmed.ncbi.nlm.nih.gov/18846108/)

[Shibue et al., Non-canonical p53 activation of PUMA (2013)](https://pubmed.ncbi.nlm.nih.gov/23211775/)

[Hao et al., PUMA in Alzheimer's disease (2015)](https://pubmed.ncbi.nlm.nih.gov/25894085/)

[Uo et al., PUMA in Parkinson's disease (2013)](https://pubmed.ncbi.nlm.nih.gov/23526720/)

[Gomez-Lazaro et al., PUMA and mitochondrial apoptosis (2008)](https://pubmed.ncbi.nlm.nih.gov/18593950/)

[Wan et al., PUMA is required for p53-mediated neurodegeneration (2008)](https://pubmed.ncbi.nlm.nih.gov/18626005/)

[Jeong et al., p53 transcriptional activation of PUMA in neurons (2007)](https://pubmed.ncbi.nlm.nih.gov/17568779/)

[Hitomi et al., PUMA in cerebral ischemia (2008)](https://pubmed.ncbi.nlm.nih.gov/18566447/)

[Morrell et al., PUMA in traumatic brain injury (2013)](https://pubmed.ncbi.nlm.nih.gov/23826869/)

[Engler et al., PUMA in ALS (2021)](https://pubmed.ncbi.nlm.nih.gov/33568814/)

[Liu et al., PUMA and neuroinflammation (2018)](https://pubmed.ncbi.nlm.nih.gov/29883675/)

[Gao et al., PUMA in retinal neurodegeneration (2019)](https://pubmed.ncbi.nlm.nih.gov/30760004/)

[Akhtar et al., Targeting PUMA for neuroprotection (2020)](https://pubmed.ncbi.nlm.nih.gov/32877950/)

[Inoue et al., PUMA and ER stress (2019)](https://pubmed.ncbi.nlm.nih.gov/31122215/)

[Cheng et al., PUMA in stroke therapy (2016)](https://pubmed.ncbi.nlm.nih.gov/26988930/)

[Sun et al., PUMA and autophagy crosstalk (2020)](https://pubmed.ncbi.nlm.nih.gov/32919442/)

[Levin et al., PUMA as biomarker in neurodegeneration (2022)](https://pubmed.ncbi.nlm.nih.gov/35128546/)

Pathway Diagram

The following diagram shows the key molecular relationships involving BBC3 discovered through SciDEX knowledge graph analysis:

Mermaid diagram (expand to render)

📖 View canonical wiki page →

Related Entities

BBC3

▸Metadataorigin_type: v1_polymorphic_backfill

slug	genes-bbc3
kg_node_id	BBC3
entity_type	gene
origin_type	v1_polymorphic_backfill
source_table	wiki_pages
wiki_page_id	wp-375ab67d9edf
__merged_from	{'merged_at': '2026-05-13', 'unprefixed_id': 'genes-bbc3'}
_schema_version	1

📊 Evidence Profile Foundational

Evidence Balance

+0%

Certainty

50%

Debates

0

Incoming

10

Outgoing

18

0 supporting 0 contradicting 0 neutral

View full evidence profile →

Public annotations (0)Annotate on Hypothes.is →

No public annotations yet.

📗 Cite This Artifact

BBC3

BBC3 — BCL2 Binding Component 3 (PUMA)

Overview

BBC3 — BCL2 Binding Component 3 (PUMA)

Overview

Normal Function

Protein Structure and Classification

BH3 Domain Function

Cellular Functions

Basal Expression

Regulation of PUMA Expression

p53-Dependent Regulation

p53-Independent Pathways

Post-Transcriptional Regulation

Role in Neurodegeneration

Alzheimer's Disease

Amyloid-Beta Toxicity

Tau Pathology

Energy Failure

Key Findings from AD Research:

Parkinson's Disease

α-Synuclein Toxicity

Mitochondrial Dysfunction

Key Findings from PD Research:

Stroke and Cerebral Ischemia

Excitotoxicity

Reperfusion Injury

Neuroprotection

Traumatic Brain Injury

Amyotrophic Lateral Sclerosis (ALS)

Neuroinflammation

Mechanisms of Neuronal Death

Mitochondrial Apoptosis Pathway

Key Steps:

Additional Mechanisms

ER Stress-Mediated Death

Autophagy Interactions

Regulation in Neurons

Anti-Apoptotic Protectors

Neurotrophic Factor Protection

Activity-Dependent Regulation

Therapeutic Targeting

Rationale for Targeting PUMA

Therapeutic Strategies

BH3 Mimetics

Gene Therapy Approaches

Modulation of Upstream Signals

Challenges

Biomarker Potential

PUMA as a Biomarker

Fluid Biomarkers

Tissue Biomarkers

Clinical Applications

Cross-Linking to Related Topics

Apoptosis and Cell Death

Related Genes

Related Diseases

Therapeutic Approaches

Research Directions

Current Understanding

Emerging Research Areas

Preclinical and Clinical Trials

Key Publications

Cross-References

See Also

External Links

References

Pathway Diagram

💬 Discussion